fbpx
  • Panels
    • ePlex Panels
      • Respiratory
      • Blood Culture
    • XT-8 Panels
  • Systems
    • ePlex System
      • Software Solutions
      • Patient Safety
    • XT-8 System
  • Company
    • The GenMark Story
    • Careers
      • Opportunities
    • Newsroom
  • Education
    • Disease State
      • Sepsis
      • Respiratory Infections
      • Hepatitis C
      • GI Infections
    • Technology
    • Resources
  • Support
    • Contact Us
    • FAQs
    • Safety Data Sheets (SDS)
    • Your Long-Term Partner
  • Customer Resource Center
Select your region:
  • International
    • United States
SELECT YOUR REGION:
  • International
    • United States
| CONTACT US | CUSTOMER RESOURCE CENTER
GenMark
  • Panels
    • ePlex Panels
      • Respiratory Pathogen Panels
      • Blood Culture
  • Systems
    • ePlex System
      • Software Solutions
      • Patient Safety
  • Company
    • The GenMark Story
    • Careers
    • Newsroom
  • Education
    • Disease State
      • Sepsis
      • Respiratory Infections
      • GI Infections
    • Technology
    • Resources
  • Support
    • Contact Us
    • FAQs
    • Safety Data Sheets (SDS)
    • Long-Term Partner
  • Customer Resource Center

 

Blood Culture Identification (BCID) Panels

The More You Detect, The Better You Protect

GenMark’s ePlex® Blood Culture Identification (BCID) Panels provide broad coverage of organisms that can lead to sepsis along with their resistance genes. This broad coverage means that about 95% of currently identified bloodstream infections can be detected early with the ePlex BCID Panels, compared to other panels that detect significantly fewer sepsis-causing bacteria and fungi (Table 1).

 

VIEW SUPPORTING LITERATURE

 

 

 

 

 

ePlex BCID Panels: Sepsis and COVID-19

COVID-19 grew to pandemic proportions in 2020, with global case numbers approaching 100M by the end of the year. Although most cases are mild, some patients are at higher risk, with an overall mortality rate of >2%1. The mortality rate of sepsis can be as high as 75% depending on the agent causing infection2 and because the clinical presentation of COVID-19 and sepsis can be similar, antimicrobial use has increased during the pandemic3 further driving antimicrobial resistance. Rapid detection or rule-out of bacterial or fungal co-infections and secondary infections can help reduce unnecessary or inadequate antimicrobial therapy.

 

 

DOWNLOAD SEPSIS AND COVID-19 DATA INSIGHTS

 

 

 

Early Identification Helps Improve Patient Outcomes

It is estimated that 20-30% of patients receive ineffective initial antibiotic therapy and the mortality rate for these patients increases up to 7.6% for every hour effective antibiotics are delayed.4,5

 

The ePlex BCID Panels aid clinicians in the identification of bacterial and fungal organisms as well as antibiotic resistance genes within approximately 1.5 hours of blood culture bottle positivity, allowing treatment decisions to occur days earlier than with conventional methods. Unique ePlex solutions, like the ePlex Templated Comments Module, can help to improve antimicrobial stewardship and optimize patient care.

 

 

 

The Most Comprehensive Molecular Blood Culture Panels

The ePlex BCID Panels offer the broadest coverage of organisms and resistance markers that cause bloodstream infections (BSI) and can lead to sepsis, including anaerobes and multi-drug resistant organisms (MDRO), as well as common and emerging fungal pathogens (Table 1). The ePlex BCID Fungal Pathogen (FP) Panel was the first FDA-cleared multiplex molecular panel to include Candida auris, a multi-drug resistant fungal organism that is increasing in prevalence around the world.6

 

Table 1: ePlex BCID Panels detect more of the organisms that cause Bloodstream Infections than other multiplex panels

% Organism Inclusivity

5 US Hospitals

GenMark

Clinical Study

Potula*

Weighted

Average

Number of samples (n)

15793

1979

2746

20518

ePlex BCID Panel

94.3%

93.6%

97.8%

94.6%

Competitor 1 BCID

84.3%

86.6%

89.6%

85.3%

Competitor 1 BCID v2

86.8%

89.1%

90.4%

86.4%

Competitor 2 BC

83.1%

83.0%

85.5%

83.5%

Competitor 3  BC ID

78.1%

82.1%

85.9%

73.3%

Competitor 3 BC AST

68.5%

74.4%

80.9%

64.5%

Blood culture panel target inclusivity based on prevalence of organisms that cause bloodstream infections in the United States – 3 clinical sample sets: a) Combined 5 US geographically diverse hospitals (n=15,793), b) GenMark’s prospective clinical trial database (n=1976 from 10 US clinical study sites), c) Potula et. al. (2015) MLO ; https://www.mlo-online.com/automated-blood-culture-testing.php (n = 2,569)2

 

 

 

Resistance Genes Inform Rapid Clinical Decision Making

The ePlex BCID Panels include 4 gram-positive and 10 gram-negative resistance genes that can be detected days earlier than conventional antimicrobial susceptibility tests (AST), enabling earlier escalation of therapy for resistant organisms or de-escalation of empirical antimicrobials in the case of common contaminants or when a narrower antibiotic is more appropriate. Rapid detection of antibiotic resistance genes when applied with local epidemiology of resistance, has been shown to have a high percent agreement with subsequent phenotypic susceptibility testing, allowing for recommendation of a targeted therapy earlier.8

 

 

 

Rapidly Rule-Out Blood Culture Contamination

As much as 15 to 30% of positive blood cultures may be due to contaminants which can result in continuation of unnecessary antibiotics9. ePlex BCID Panels are designed to allow labs to more rapidly differentiate a contaminant from a true infection, enabling rapid de-escalation and discharge of patients with a bloodstream infection 2-3 days earlier than conventional methods.
Common contaminants included on the ePlex BCID-GP panel but not on most competitor’s panels include:

  • Bacillus subtilis
  • Corynebacterium
  • Cutibacterium acnes
  • Micrococcus
  • Lactobacillus

 

For more information on the ePlex BCID Panels

 

BCID Clinical Brochure   BCID TriFold

 

 

 

What Our Customers Are Saying

[P]

The True Sample-to-Answer Solution® 

To learn more about the Blood Culture Identification (BCID) Panels or to schedule a demonstration, contact us at 1.800.373.6767 or click below

 

CONTACT US

 

 

 

 

  1. Johns Hopkins University of Medicine Coronavirus Resource Center https://coronavirus.jhu.edu/map.html
  2. Pfaller MA, et al.(2007) Clin Micro Rev 20(1):133-63
  3. Makary, M. et. al. (2021) MedPage Today, https://www.medpagetoday.com/blogs/marty-makary/90795
  4. IDSA: Better Tests Better Care, The Promise of Next Generation Diagnostics.
  5. Kumar, et al. (2006) Crit Care Med. 34 (6):1589-1596
  6. Singh, N. (2001) Clin Infect Dis, 33(10):1692-1696
  7. Detection rate based on panel inclusivity only, not a sensitivity/performance claim
  8. Pogue, JM, et al. (2018) Antimicrob Agents Chemother: 62(5):e02538-17
  9. Murray, P. et. al. (2012), Crit Care Med,Current Approaches to the Diagnosis of Bacterial and Fungal Bloodstream Infections for the ICU.

GenMark Diagnostics, Inc.
5964 La Place Court
Carlsbad, CA 92008

 

© Copyright 2023 GenMark Diagnostics, Inc.
All rights reserved.

 

info@genmarkdx.com
P: +1 760-448-4300
F: +1 760-448-4301

 

Legal | Privacy Policy

 

 

This website uses cookies to improve your experience. Read More. You can opt-out if you wish. Change settingsACCEPT REJECT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
Popup Button